the Effect of Carbetocin in Decreasing Intraoperative Blood Loss in Abdominal Myomectomy
- Registration Number
- NCT04083625
- Lead Sponsor
- Cairo University
- Brief Summary
To investigate the effectiveness of carbetocin on reducing intraoperative blood loss during abdominal myomectomy
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 138
Inclusion Criteria
-
• Patients presenting for abdominal myomectomy with documented uterine fibroids on pelvic imaging
- Age ≥ 25 years and ≤ 50 years
- Pre-operative hemoglobin >10 g/dl
- Ability to understand and the willingness to sign a written informed consent.
- Admissible medical/surgical history
- Five or less symptomatic uterine myomas
- symptomatic stage 3 to 6 fibroids, according to FIGO staging
Exclusion Criteria
-
• Post-menopausal women
- Patients with known bleeding/clotting disorders
- Patients with a history of gynecologic malignancy
- Hypertension.
- Cardiac and Pulmonary diseases.
- History of allergic reactions attributed to carbetocin
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description placebo placebo 10 cm syringe normal saline IV given just before skin incision of myomectomy. carbetocin carbetocin 100 mcg 100microgram in 10 cm syringe carbetocin IV just before skin incision of myomectomy.
- Primary Outcome Measures
Name Time Method Mean amount of intraoperative blood loss intraoperative Mean amount of intraoperative blood loss in ml
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Giza hospital
🇪🇬Giza, Egypt
Giza hospital🇪🇬Giza, Egypt